eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2020
vol. 71
 
Share:
Share:
more
 
 
abstract:

The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

Izabela Siemińska
1
,
Edyta Rychlicka-Buniowska
2
,
Janusz Jaszczyński
3
,
Mikołaj Palaczyński
3
,
Karolina Bukowska-Strakova
1
,
Janusz Ryś
4
,
Jan Dumański
2
,
Maciej Siedlar
1
,
Jarosław Baran
1

1.
Department of Clinical Immunology, Institute of Pediatrics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
2.
Department of Immunology, Genetics and Pathology, Medical Genetics and Genomics, Uppsala Universitet, Uppsala, Sweden
3.
Department of Surgery, National Research Institute of Oncology, Krakow Branch, Krakow, Poland
4.
Department of Pathology, National Research Institute of Oncology, Krakow Branch, Krakow, Poland
Pol J Pathol 2020; 71 (1): 46-54
Online publish date: 2020/05/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Prostate cancer is one of the most frequent cancers in men. Although several treatment options exist, their clinical effectiveness is still not satisfactory. One the possible reason of such situation might be the presence of myeloid-derived suppressor cells (MDSC) and their pro-tumorigenic activity. MDSC possess immunosuppressive ability and in many studies were shown to support tumor development and progression. In this study we addressed the question whether commonly used therapies of prostate cancer affect the level of MDSC populations in the patients’ blood. We compared the level of granulocytic (Gr-MDSC), monocytic (Mo-MDSC) and early stage MDSC (eMDSC) in the blood of patients at different clinical stage and different tumor grading scores, who underwent either surgery or hormonal therapy alone or were given a combined treatment, including e.g. radiotherapy. The obtained results showed that the level of Gr-MDSC was significantly lower in all treated patients comparing to untreated group. On the other hand, surgery or hormonal therapy alone did not affect the level of Mo-MDSC. These results were independent of the PSA level, the tumor grading and clinical stage of the patients. In conclusion, we suggest that Mo-MDSC should be considered as a potential therapy target in the course of prostate cancer treatment to enhance its anti-tumor effectiveness.
keywords:

prostate cancer (PC), myeloid-derived suppressor cells (MDSC), flow cytometry, prostate specific antigen (PSA)

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe